🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Next month, we'll be heading to #ISAL2023 to speak with experts who will bring you the latest in acute leukemias! Find out more below: 👉ow.ly/LMNT50MWQzz👈 #ISALXVIII #AMLsm #ALLsm #LeuSM #HemOnc MariSubklewe International Symposium Acute Leukemias - Munich

#ISAL2023 | MariSubklewe of Universität München shares some insights into the current status of bispecifics in AML and challenges to overcome. Watch here: 👉ow.ly/2Klo50Nr3EF👈 #AMLsm #LeuSM #ImmunoOnc #HemOnc

Great to participate in this study aiming to identify infection vs CRS after #CART therapy, always a pleasure with Kai Rejeski MariSubklewe

Filled with great joy & gratitude for an inspiring networking event of #FAME, a newly founded network of female university professors at the LMU Medical Faculty that fosters female careers and prepares the next generation of female leaders in academic medicine. Many more to come.

RWE of EU & US practice patterns of Immune Effector Cell Associated Hematotoxicity (ICAHT) post #CART. Fantastic collaborative work with @EBMT @EHA and international #CAR community. Check out our survey journals.lww.com/hemasphere/Ful…. Kai Rejeski Ibrahim Yakoub-Agha @ annasureda5

Brilliant Habilitation Presentation by Kai Rejeski last nite at the LMU medical faculty colloquium. Congrats to this impressive publication track record - honored to be one of his mentors.

Real honor to present our consensus grading and best practice recommendations for immune effector cell-associated hematotoxicity (ICAHT) on behalf of European Hematology Association and The EBMT and entire team today at #EHA23! Manuscript out in parallel @BloodJournal ashpublications.org/blood/article/…

Kudos to the #EHA #EBMT team on putting together #ICAHT consensus guidelines now published in @BloodJournal. Grateful for this incredible European collaboration and a special shoutout to Kai Rejeski

Kai Rejeski MariSubklewe you made it to the icml highlights👍

Professorinnen @LMU – gemeinsam für die neue Ära der Spitzenmedizin. Female professors @LMU_Uniklinikum - together for the new era of cutting-edge medicine. Universität München; #WomenInMedicine; #WomenInSTEM #femalescientists; #academia; #female; #equality #Diversity

Great to see our European Hematology Association and The EBMT consensus guidelines article on immune effector cell-associated hematotoxicity out in full print in @BloodJournal ! 🎉🎉🎉 Very proud of this European team effort! ashpublications.org/blood/article/…

Check out our European Hematology Association The EBMT consensus guidelines for a new distinct toxicity category of immune effector cell therapy (CAR-T, BsAb): ICAHT! See link above for the accompanying commentary ! Also featured in the @BloodJournal podcast 👇 ashpublications.org/blood/pages/bl…

How does the gut microbiome affect the efficacy of CAR T-cell therapy in patients with hematological malignancies? Prof. MariSubklewe discusses in our podcast. Full episode available below! 👉 bit.ly/42S9xy1 👈 #OncTwitter #BloodCancer #HaemOnc

#ESHAL2024 Many thanks to Dombret Hervé @Gossenkoppele Christoph Röllig Wendy Stock for putting together such an exciting program to all faculty for a great meeting & to all participants for the lively interaction! See you next year for #ESHALL2025 & #ESHAML2025 #ESHCONFERENCES

Going beyond Cancer with T cell engagers: First-in-human report on a CD19 TCE for safe & successful treatment in systemic sclerosis. EJC in press. @OncologyAdvance

18 LMU scientists made the "#HighlyCitedResearchers 2024" list published by the analytics company Clarivate for Academia & Government, which places them among the most successful in their respective fields. Congratulations on this remarkable achievement! 🎉 #HighlyCited2024 lmu.de/en/newsroom/ne…

Don't miss our excellent interview from the #EBMT25 meeting earlier this week in which MariSubklewe of Universität München speaks on the classification & management of hematotoxicity after #CARTCell therapy. Watch here: 👉 ow.ly/XOkq50VtOnr 👈 #ImmunoOnc #HemOnc The EBMT

🚨Hot off the press 🚨 A lesser-known vulnerability in CAR T-cell therapy: Sarcopenia. New in CCR AACR Predicts ↑ NRM 1/3 patients lose >10% muscle by D30 Linked to fatty acid catabolism With Michael Jain Kai Rejeski MariSubklewe Frederick L. Locke pubmed.ncbi.nlm.nih.gov/40238583/

New in @BloodJournal: STING activation boosts CD33xCD3 mediated T cell cytotoxicity in #AML by creating an IFN-g- driven feedback loop. Happy to co-lead this with @VeitHornung, and kudos to first authors Andreas Linder & Daniel Nixdorf ! doi.org/10.1182/blood.…

150+ women from all career stages came together at #FAME2025 – Females in Academic Medicine – at Universität München's Medical Faculty. A vibrant, strong space for exchange, inspiration & solidarity. Thanks to @WiebkeArlt, @AnnaFrebel & all who made it possible. #ConnectForChange